Timeline of approved compounds in MS
Developed by Khawai.
This interactive timeline presents the key milestones in the development of the 12 currently available treatments in MS.
- The overview displays general information on the compounds and their approval dates. The timelines begin at the date of the first patient visit of the oldest clinical trial, and they end with the date of the last patient visit of the most recently completed and published clinical trial.
- Click on one of the gray compound buttons to display information on its phase 2 and phase 3 clinical trials.
- Hover over the chart elements to display detailed information.
- On the individual compound pages, clicking on any of the individual clinical-trial timelines will take you to a reference to the published paper describing that trial. Within that reference, you’ll find a link to the paper’s abstract.
- Dimethyl fumarate
- Glatiramer acetate
- Interferon beta-1a (including Avonex, Plegridy, and Rebif)
- Interferon beta-1b
The data were collected through January 10, 2015.
- Approved (FDA/EMA) compound
- Completed phase 2 / Completed phase 3
- Unapproved compounds
- On-going trials
- Pilot study / Phase 4
A Gantt chart is a type of bar chart, first developed by Karol Adamiecki in 1896, and independently by Henry Gantt in the 1910s, that illustrates a project schedule.
Gantt charts illustrate the start and finish dates of the terminal elements and summary elements of a project.